Catalog No.
Product Name
Application
Product Information
Citations
-
STING Agonist
IACS-8803 disodium is a potent cyclic dinucleotide and a selective STING agonist. It activates the STING pathway, leading to enhanced immune responses against tumors. This compound is utilized in research related to cancer immunotherapy and the modulation of immune signaling pathways. -
STING Agonist
Dazostinag disodium is a potent STING agonist that activates the STING signaling pathway, leading to the production of type I interferons. This compound enhances immune responses, resulting in complete tumor regressions and the establishment of long-lasting memory T-cell immunity. Dazostinag disodium is valuable for research applications focused on cancer immunotherapy and the modulation of the immune system. -
STING Agonist
diABZI-C2-NH2 is a potent STING (Stimulator of Interferon Genes) agonist that features a primary amine group. This compound activates the STING pathway, leading to enhanced type I interferon production and immune response modulation. diABZI-C2-NH2 is valuable for research applications focused on immunotherapy, autoimmunity, and infectious disease, making it a key tool in studying the role of STING in immune signaling. -
STING Inhibitor
STING-IN-3 is a potent inhibitor of the stimulator of interferon genes (STING), specifically targeting both human and murine STING. It covalently modifies the conserved transmembrane cysteine residue at position 91, effectively preventing activation-induced palmitoylation. This activity provides valuable utility in research applications exploring STING-related pathways in immune response and therapeutic interventions in autoimmune diseases and cancer. -
STING Inhibitor
SN-001 is a selective inhibitor of the STING (Stimulator of Interferon Genes) pathway, exhibiting an IC50 of 3.82 μM. This compound is valuable for investigating the role of STING in immune responses and inflammatory diseases. Its inhibitory activity allows for the evaluation of STING's effects on cytokine production and other immune-related pathways, making it a useful tool for research in immunology and drug development. -
STING Inhibitor
STING-IN-4 is a potent STING inhibitor that effectively reduces the expression and activation of STING and nuclear factor-κB (NF-κB) signaling pathways. This compound exhibits significant anti-inflammatory activity, making it a valuable tool for investigating sepsis and related inflammatory conditions. Researchers can utilize STING-IN-4 to explore the therapeutic potential of modulating STING activity in various biological contexts. -
STING Agonist
STING agonist-23 is a small-molecule STING agonist that functions non-nucleotidally to activate the STING pathway. This enhancement leads to increased phosphorylation of STING, TBK1, and IRF3, resulting in elevated production of key cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells. STING agonist-23 is also shown to exhibit antiviral activity against SARS-CoV strains, making it a valuable tool for immunotherapy and virology research. -
STING Agonist
MSA-2 dimer is a selective, orally active non-nucleotide STING agonist that demonstrates a binding affinity (Kd) of 145 μM. This compound promotes long-term antitumor effects and enhances immunogenic activity by non-covalently interacting with STING in a dimeric form, offering superior permeability compared to cyclic dinucleotides. MSA-2 dimer is particularly valuable for research into cancer immunotherapy and the modulation of innate immune responses. -
STING Agonist
SR-717 free acid is a non-nucleotide STING agonist that demonstrates effective activation in immune responses, exhibiting EC50 values of 2.1 μM and 2.2 μM in ISG-THP1 wild-type and cGAS knockout cell lines, respectively. This compound serves as a stable cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) mimetic, enhancing antitumor activity through stimulation of the STING pathway. Its potential applications in cancer immunotherapy and the study of innate immunity make it a valuable tool for researchers in the field of immunology. -
STING Antagonist
STING antagonist-2 is a potent inhibitor of the Stimulator of Interferon Genes (STING), exhibiting a pIC50 of 8.9. This compound is primarily utilized in immunity research to investigate the modulation of STING-mediated immune responses. Its application extends to studies focused on immune evasion and potential therapeutic approaches in autoimmune disorders. -
STING Inhibitor
STING-IN-7 is a potent inhibitor of the Stimulator of Interferon Genes (STING) pathway, demonstrating an IC50 of 11.5 nM. This compound effectively inhibits the phosphorylation of STING, interferon regulatory factor 3 (IRF3), and TANK-binding kinase 1 (TBK1). STING-IN-7 is valuable for investigating the role of STING modulation in autoimmune and inflammatory disease research. -
STING Modulator
SB24011 is a selective STING modulator that inhibits the TRIM29-STING protein-protein interaction. By binding to STING, it effectively prevents TRIM29-induced K48-linked ubiquitination, leading to an increase in intracellular STING protein levels. This compound promotes the expression of inflammatory cytokines and enhances STING-mediated immune responses, demonstrating abscopal antitumor activity that stimulates tumor regression and T cell infiltration. SB24011 is particularly relevant for research on colon cancer and melanoma, showing potential synergy when used in conjunction with STING agonists or anti-PD1 antibodies. -
STING Agonist
diABZI STING Agonist-1 (tautomerism) is a selective agonist of the STING (Stimulator of Interferon Genes) receptor, enhancing innate immune responses. It exhibits potent biological activity, with EC50 values of 130 nM in human and 186 nM in mouse systems. This compound is valuable for research applications focused on immunotherapy, cancer treatment, and studies involving the modulation of immune pathways. -
STING Agonist
STING agonist-17 is a potent STING agonist that activates the STING pathway with an IC50 value of 0.062 nM. This compound exhibits significant anti-cancer activity, promoting immune response and tumor immunization. It is valuable for research applications targeting cancer therapy and immune modulation. -
STING Agonist
STING agonist-16 is a specific stimulator of interferon genes (STING) that activates the intrinsic immune response. This compound exhibits significant antiviral and antitumor activities by promoting the production of type I interferons and enhancing immune cell activation. STING agonist-16 is valuable for research applications focused on cancer immunotherapy and viral infections. -
STING Agonist
STING agonist-7 is a non-nucleotide agonist that selectively activates the mouse stimulator of interferon genes (STING). This compound has been shown to induce immune responses by enhancing type I interferon signaling in murine models. Due to its specific binding affinity, STING agonist-7 is a valuable tool for research into the immune system and the study of STING pathway-related diseases, although it exhibits poor membrane permeability. -
STING PROTAC Degrader
PROTAC STING degrader-3 is a potent STING PROTAC degrader that operates through the ubiquitin-proteasome pathway, exhibiting a DC50 of 0.62 μM. This compound facilitates STING degradation, resulting in the inhibition of STING/TBK1/NF-κB signaling, thereby exerting notable anti-inflammatory effects. Additionally, PROTAC STING degrader-3 demonstrates renal protective properties and serves as a valuable tool for investigating acute kidney injury (AKI). -
STING Inhibitor
STING-IN-15 is a potent STING inhibitor that exhibits an IC50 of 116 nM against human STING and 96.3 nM against mouse STING. It effectively disrupts the STING signaling pathway in cellular models, leading to a decrease in the secretion of IFN-β and IP-10, and downregulating the expression of key inflammatory markers such as ISG15, ISG56, and TNF-α. Additionally, STING-IN-15 shows promise in reducing systemic and renal inflammation triggered by STING agonists in murine models, thereby mitigating tissue damage and the overexpression of interferon-related genes. This compound is valuable for research into acute kidney injury and various autoimmune/inflammatory diseases. -
STING Agonist
diABZI-V/C-Mal is a potent STING agonist, exhibiting an EC50 of 314 nM in TH1 dual reporter cells. This compound activates the STING pathway, leading to the subsequent activation of the IRF3 signaling pathway, which plays a critical role in immune response. Additionally, diABZI-V/C-Mal serves as a substrate for Cathepsin B, allowing for the regeneration of diABZI-NH2 through enzymatic cleavage. It is a valuable tool for research in immunology and cancer therapy. -
STING Agonist
diABZI-Mal is a STING agonist featuring a maleimide moiety that facilitates the synthesis of conjugates. It effectively activates the cGAS-STING pathway, leading to the production of type I interferons and promoting the maturation of dendritic cells. Additionally, diABZI-Mal enhances CD8+ T cell responses and has demonstrated the ability to inhibit tumor growth, making it a valuable tool in cancer immunotherapy research. -
STING Inhibitor
H-151 Alkyne is a selective inhibitor of STING (Stimulator of Interferon Genes). This compound demonstrates potential for modulating immune responses, making it valuable in the study of autoimmune diseases such as systemic lupus erythematosus and scleroderma, as well as autoinflammatory conditions. Its ability to interfere with STING pathways allows researchers to explore therapeutic strategies targeting these diseases. -
STING Agonist
STING agonist-26 (CF508) is a small-molecule agonist that activates the Stimulator of Interferon Genes (STING) pathway. This compound enhances the phosphorylation of STING, TBK1, and IRF3, leading to increased production of key cytokines, including IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5, in tumor cells. STING agonist-26 shows potential in the study of antiviral responses, particularly against SARS-CoV strains, making it a valuable tool for research in immunotherapy and inflammation. -
STING Agonist
Ulevostinag is a potent STING (stimulator of interferon genes) agonist that activates the immune response through the modulation of cyclic dinucleotide pathways. By stimulating STING, Ulevostinag enhances the production of type I interferons, which play a crucial role in the anti-tumor immune response. This compound is primarily utilized in research focused on immuno-oncology, particularly in the exploration of new therapeutic strategies for cancer treatment. -
STING Agonist
BDW568 is a potent STING agonist, specifically designed to selectively activate the human STINGA230 allele. This compound effectively stimulates STINGA230-engineered macrophages, making it a valuable tool in macrophage-based immunotherapy research. Its ability to modulate immune responses positions BDW568 as a significant candidate for enhancing anti-tumor immunity and other immune-related studies. -
STING Agonist
STING agonist-14 (compound 12b) is a potent agonist of stimulator of interferon genes (STING), demonstrating efficacy in various species. It activates the STING pathway by directly binding to human STING, leading to enhanced immune responses. This compound is suitable for research applications focused on tumor biology and viral infections, facilitating the study of immune modulation and potential therapeutic strategies. -
STING Agonist
MK-2118 is a GMP-synthesized STING agonist that activates the stimulator of interferon genes pathway, enhancing innate immune responses. This compound demonstrates potential in inhibiting advanced or metastatic solid tumors as well as lymphomas. Its ability to modulate immune activity makes MK-2118 a valuable tool for cancer immunotherapy research. -
STING Agonist
STING agonist-15 is a potent stimulator of the STING (Stimulator of Interferon Genes) pathway, which plays a crucial role in immune surveillance and response to tumors. This compound enhances the production of type I interferons and other cytokines, promoting anti-tumor immunity and modulating inflammatory responses. It is particularly valuable for cancer research and studying immune-related therapeutic approaches. -
STING Agonist
IACS-8803 is a potent cyclic dinucleotide STING agonist that acts by activating the stimulator of interferon genes (STING) pathway, leading to enhanced immune responses. This compound demonstrates significant systemic antitumor efficacy, making it a valuable tool for cancer immunotherapy research. Its ability to modulate the immune microenvironment positions IACS-8803 as a promising candidate for studies focused on tumor immunogenicity and therapeutic interventions. -
STING Agonist
STING agonist-8 is a highly effective STING agonist, demonstrating an EC50 of 27 nM in THP1-Dual KI-hSTING-R232 cells. This compound enhances the activity of the STING pathway, making it valuable for research applications focused on cancer immunotherapy and innate immune signaling. STING agonist-8 can facilitate studies exploring the therapeutic potential of STING-mediated immune responses. -
STING Agonist
STING agonist-46 is a potent STING agonist that activates the stimulator of interferon genes (STING) signaling pathway, leading to the phosphorylation of TBK1 and IRF3 as well as the secretion of key cytokines such as IFN-β and IP-10. By directly binding to STING, it enhances thermal stability and elicits significant anti-tumor effects in mouse models, including B16F10, CT26, and 4T1. This compound is suitable for research applications focused on cancer immunotherapy and the elucidation of STING-related immune responses. -
STING Agonist
ZSA-51 is a potent STING agonist that exhibits significant anticancer activity. This compound enhances the immune response by remodeling the immune microenvironment in both tumor tissues and lymph nodes. Its ability to stimulate STING pathways makes it a valuable tool for cancer immunotherapy research. -
STING Inhibitor
STING-IN-5 is a potent inhibitor of the STING pathway, specifically targeting the STING protein to attenuate LPS-induced nitric oxide synthesis in macrophages, with an IC50 value of 1.15 μM. This compound effectively reduces inflammatory responses, making it valuable for research focused on anti-inflammatory diseases and sepsis. Its ability to modulate immune responses highlights its potential in elucidating the role of STING in various pathological contexts. -
STING Agonist
Dazostinag is a potent agonist of the stimulator of interferon genes (STING) protein, demonstrating significant antineoplastic activity. This compound activates the STING pathway, leading to enhanced immune responses against tumors. Additionally, Dazostinag can be utilized as a payload in the synthesis of antibody-drug conjugates (ADCs), providing a valuable tool for targeted cancer therapies. -
STING Agonist
E7766 disodium is a macrocycle-bridged agonist that targets the Stimulator of Interferon Genes (STING) pathway, exhibiting a dissociation constant (Kd) of 40 nM. It demonstrates significant pan-genotypic activity and potent antitumor effects, making it a valuable reagent for cancer immunotherapy research. This compound is ideal for studies focusing on enhancing immune responses through STING activation. -
STING Agonist
IACS-8779 is a potent stimulator of interferon genes (STING) agonist, which activates the STING pathway to enhance immune responses. This compound demonstrates significant systemic antitumor efficacy, making it a valuable tool in cancer research and immunotherapy applications. Its ability to stimulate innate immune responses positions it as a promising candidate for further exploration in oncological studies. -
STING Agonist
BI 7446 is a cyclic dinucleotide (CDN)-based stimulator of interferon genes (STING) agonist that exhibits potent and selective activity. This compound effectively activates all five STING variants within cells, promoting immune-mediated tumor rejection. BI 7446 is suitable for applications in immuno-oncology research, facilitating the exploration of tumor immunity mechanisms. -
STING Agonist
IACS-8779 disodium is a potent stimulator of interferon genes (STING) agonist that elicits a strong activation of the STING signaling pathway. This compound demonstrates significant systemic antitumor efficacy, highlighted by its superior performance in inducing anti-tumor responses in the B16 murine model of melanoma. IACS-8779 disodium is ideal for research applications focused on cancer immunotherapy and the modulation of innate immune responses. -
STING Agonist
STING agonist-51 is a potent bis-benzimidazole compound that targets the STING (Stimulator of Interferon Genes) pathway. It activates STING to enhance the innate immune response, making it a valuable tool for cancer research. This agonist can be used to investigate immune modulation and its therapeutic potential in oncology. -
STING Modulator
STING modulator-4 (compound AIH05) is a competitive modulator of the Stimulator of Interferon Genes (STING), exhibiting a Ki of 0.0933 μM for the R232H variant of STING. This compound demonstrates biological activity with an EC50 value exceeding 10 μM for phosphorylated IRF3 in THP-1 cells. STING modulator-4 is significant for research in immunology and enhances understanding of STING-mediated signaling pathways. -
STING Agonist
STING agonist-28 is a non-nucleotide small-molecule that serves as a potent agonist for the Stimulator of Interferon Genes (STING) pathway. It activates STING, leading to the phosphorylation of key proteins including TBK1 and IRF3. This compound significantly enhances the production of pro-inflammatory cytokines such as IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5 in tumor cells, making it valuable for immunotherapy research. Additionally, STING agonist-28 demonstrates antiviral activity against various SARS-CoV strains, highlighting its potential in antiviral research applications. -
STING Ligand
STING ligand-2 is a selective ligand for the stimulator of interferon genes (STING) pathway. This compound is integral in the development of PROTAC degraders, specifically STING-IN-10, enabling targeted protein degradation. Its key biological activity is the enhancement of immune responses, making it valuable for research in immunotherapy and cancer treatment applications. -
STING Agonist
STING Agonist-24 is a small-molecule STING agonist that activates the STING pathway, leading to increased phosphorylation of STING, TBK1, and IRF3. This compound enhances the expression of key pro-inflammatory cytokines and chemokines, including IFN-β, IL-6, CXCL-10, TNF-α, ISG-15, and CCL-5, in tumor cells. Additionally, STING Agonist-24 demonstrates antiviral activity against various strains of SARS-CoV, making it a valuable tool for research in immunotherapy and viral pathogenesis. -
STING Agonist
STING agonist-42 is a potent agonist of the stimulator of interferon genes (STING) pathway. It effectively activates STING in THP-1 and RAW 264.7 cells, demonstrating EC50 values of 0.06 μM and 14.15 μM, respectively. This compound can be utilized in research focused on immune modulation and the exploration of STING-related signaling pathways in various biological contexts. -
STING Agonist
C-di-IMP (Cyclic-di-IMP) is a small molecule that acts as a stimulator of the STING (Stimulator of Interferon Genes) pathway. It promotes immune activation and has significant implications in the study of cancer immunotherapy. This compound is valuable for research aimed at enhancing anti-tumor immunity and understanding the role of STING in modulating immune responses. -
STING Activator
STING agonist-11 (Compound 92) is a potent small molecule cyclic urea that selectively activates the stimulator of interferon genes (STING) pathway. With an EC50 of 18 nM, it enhances the immune response, making it a valuable tool in immunotherapy research. Its ability to modulate STING activity positions it for potential applications in cancer treatment and infectious disease models. -
STING Agonist
STING agonist-31 is a potent stimulator of the STING pathway, exhibiting EC50 values of 0.24 μM for human STING (h-STING) and 39.51 μM for mouse STING (m-STING). This compound demonstrates significant antitumor activity, making it an important tool for cancer research. It is suitable for studying the mechanisms of innate immunity and potential therapeutic applications in oncology. -
STING Agonist
STING Agonist-27 is a non-nucleotide small-molecule compound designed to activate the STING (Stimulator of Interferon Genes) pathway. This agonist showcases significant biological activity against various strains of SARS-CoV, making it valuable for research in antiviral mechanisms and immune modulation. Its application in studies targeting STING activation provides insights into therapeutic strategies for combating viral infections and enhancing innate immunity. -
STING Agonist
Antitumor agent-114 is a potent stimulator of interferon genes (STING) agonist. It effectively activates immune responses, leading to reduced tumor volume in preclinical mouse models of breast cancer. This compound is valuable for research in immunology and cancer therapy, contributing insights into immune modulation and tumor microenvironment interactions. -
PROTAC STING Degrader
PROTAC STING Degrader-2 is a targeted protein degrader that specifically induces the degradation of the Stimulator of Interferon Genes (STING) through a covalent interaction with STING and an E3 ubiquitin ligase. With a DC50 value of 0.53 μM, this compound facilitates the study of STING's biological functions, particularly in the context of autoinflammatory and autoimmune diseases. This reagent is instrumental for researchers exploring the therapeutic potential and role of STING in immune regulation. -
STING Inhibitor
STING-IN-14 is a potent STING inhibitor with an IC50 value of 0.6 nM. This compound effectively suppresses the activation of the IRF pathway in THP1-DualTM cells, making it a valuable tool for studying the role of STING in immune responses. STING-IN-14 is particularly relevant for research focused on autoimmune diseases, contributing to a better understanding of disease mechanisms and potential therapeutic interventions.
